News
1h
Zacks Investment Research on MSNPROK Surges More Than 500% on Upbeat Data From Kidney Cell Therapy StudyShares of ProKidney Corp. PROK skyrocketed 515% yesterday after the company reported encouraging top-line data from the phase ...
ProKidney shares are trading sharply higher Wednesday morning. The stock is gaining following a marked surge on Tuesday ...
Live Updates Live Coverage Updates appear automatically as they are published. Wall Street Moves 9:53 am by Morgan Stanley ...
US clinical-stage biotech ProKidney reported statistically-significant and clinically-meaningful positive top-line results ...
4h
InvestorsHub on MSNProKidney Shares Soar After Citi Lifts Price Target to $9Shares of ProKidney Corp. (NASDAQ:PROK) jumped 65% in pre-market trading Wednesday, extending the dramatic rally seen on ...
The company also encounters competitive risks from other organizations developing therapies for chronic kidney disease.
ProKidney shares surged 500% on positive Phase 2 CKD results. Read why I remain cautious about PROK stock despite the recent ...
ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company ...
ProKidney (NASDAQ: PROK) experienced a surge of 515% during Tuesday's trading session and gained additional 8.58% after-hours ...
A mixed bag of top-line phase II data prompted stellar stock results for Prokidney Corp. and its chronic kidney disease (CKD) ...
ProKidney’s stock was the biggest gainer and most actively traded on Tuesday following “very intriguing” news regarding the ...
ProKidney shares soar on promising Rilparencel mid-stage data for chronic kidney disease. But PROK stock remains a high-risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results